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Abstract
Heterotrimeric guanine nucleotide–binding protein (G protein)–coupled receptors (GPCRs) can 
form multiprotein complexes (heteromers), which can alter the pharmacology and functions of the 
constituent receptors. Previous findings demonstrated that the Gq/11-coupled serotonin 5-HT2A 
receptor and the Gi/o-coupled metabotropic glutamate 2 (mGlu2) receptor—GPCRs that are 
involved in signaling alterations associated with psychosis—assemble into a heteromeric complex 
in the mammalian brain. In single-cell experiments with various mutant versions of the mGlu2 
receptor, we showed that stimulation of cells expressing mGlu2–5-HT2A heteromers with an 
mGlu2 agonist led to activation of Gq/11 proteins by the 5-HT2A receptors. For this crosstalk to 
occur, one of the mGlu2 subunits had to couple to Gi/o proteins, and we determined the relative 
location of the Gi/o-contacting subunit within the mGlu2 homodimer of the heteromeric complex. 
Additionally, mGlu2-dependent activation of Gq/11, but not Gi/o, was reduced in the frontal cortex 
of 5-HT2A knockout mice and was reduced in the frontal cortex of postmortem brains from 
schizophrenic patients. These findings offer structural insights into this important target in 
molecular psychiatry.
Introduction
Heterotrimeric guanine nucleotide–binding protein (G protein)–coupled receptors (GPCRs) 
represent the largest family of signaling proteins in the mammalian genome, and they are the 
most common targets for therapeutic drugs (1, 2). These heptahelical transmembrane 
proteins activate G proteins to modulate cell function (3). G proteins are grouped into four 
families (Gs, Gi/o, Gq/11, and G12) according to the degree of homology of their primary 
structure and their regulation of specific signaling events. GPCRs have been thought to 
function as monomers—a model of receptor signaling that is further supported by 
observations based on assays that measure the agonist binding and G protein coupling of a 
single purified monomeric family A GPCR, such as the β2-adrenergic receptor, rhodopsin, 
and the μ-opioid receptor (4–6). Nevertheless, it is currently widely accepted that the 
metabotropic glutamate (mGlu) receptors (which are part of the C family of GPCRs) are 
assembled into strict dimers (7). Similarly, extensive biochemical and biophysical evidence 
corroborates the existence of homodimers, heterodimers, and oligomers of family A GPCRs 
that differentially alter receptor–G protein coupling preferences and G protein–dependent 
signaling (8). Although this model of quaternary interactions is further supported by the 
increase in studies that have elucidated crystal structures of GPCRs, especially by the dimers 
found within four of the latest structures (CXCR4, μ-opioid, κ-opioid, and β1-adrenergic 
receptors) (9–13), there are a number of open questions about the structural mechanism of 
crosstalk through dimeric and oligomeric GPCR structures.
Data from studies of mutant α1B-adrenergic receptor–G protein fusions, in which either the 
G protein or the receptor was specifically deactivated, suggest that GPCRs could operate 
through an activation mechanism by which the signal would be transmitted from the 
protomer to which the ligand binds to the neighboring protomer of the homomeric receptor 
complex (14). A similar mechanism of crosstalk is well documented for the γ-aminobutyric 
acid B (GABAB) receptor, a family C GPCR. In this case, one subunit (GABAB-R1) binds 
to the agonist, whereas the other (GABAB-R2) activates the G protein (15, 16). Furthermore, 
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agonist binding to a single protomer maximally activates a signaling unit consisting of two 
dopamine D2 receptors (family A GPCRs) and a single G protein (17); however, results from 
studies of the family A GPCR leukotriene B4 receptor BLT1 argue against transactivation. 
These studies demonstrated that, although ligand binding to one protomer in the homodimer 
is associated with cross-conformational changes, a mechanism of transactivation, in which 
the ligand-free protomer would trigger the exchange of guanosine 5′-triphosphate (GTP) for 
guanosine diphosphate (GDP) on the G protein α subunit, could not be considered as a 
means for G protein activation in this case (18, 19). Much less is known about allosteric 
communication between components of heteromeric GPCR complexes.
The serotonin 5-HT2A receptor, which is a family A GPCR, and the mGlu2 receptor, which 
is a family C GPCR, have been linked to the pathophysiology of schizophrenia and other 
psychotic disorders, as well as to the mechanism of action of atypical antipsychotic drugs 
(for example, clozapine, olanzapine, and risperidone), and a new class of potential 
antipsychotic drugs that act as agonists of mGlu2 and mGlu3 receptors (for example, 
LY379268 and LY404039) (20). These two receptor subtypes are also involved in the 
molecular mechanism of action of hallucinogenic 5-HT2A receptor agonists, such as lysergic 
acid diethylamide and psilocin (21). Our previous findings demonstrated that the Gq/11-
coupled 5-HT2A receptor and the Gi/o-coupled mGlu2 receptor form a specific heteromeric 
GPCR complex in heterologous expression systems, as well as in mouse and human frontal 
cortex (22, 23). These data, however, did not address whether 5-HT2A and mGlu2 receptors 
are expressed as heterodimers or higher-order heteromeric complexes. We also demonstrated 
that this molecular proximity between 5-HT2A and mGlu2 does not occur with the closely 
related Gi/o-coupled mGlu3 receptor, and it is either rescued or disrupted with different 
mGlu2 or mGlu3 chimeric constructs. Thus, we showed that, acting through the 5-HT2A–
mGlu2 receptor heterocomplex, both serotonergic and glutamatergic ligands modulate Gq/11- 
and Gi/o-dependent signaling (24). However, although this pattern of G protein coupling 
induced by drugs bound to one receptor of the heteromer in the presence of the endogenous 
ligand of the other receptor (for example, serotonin or glutamate) predicts their 
propsychotic- and antipsychotic-like behavioral effects (24), the way in which these 
assemblies function at a molecular level has not been resolved. It is thus unclear whether 
conformational rearrangements in both protomers of the 5-HT2A–mGlu2 receptor 
heterocomplex upon ligand binding are necessary for changes in the pattern of G protein 
coupling.
Here, we focused on the ability of the mGlu2 receptor to activate Gq/11-dependent signaling 
through the 5-HT2A–mGlu2 heteromeric complex. The central question was whether agonist 
binding to the mGlu2 receptor resulted in conformational changes in the other GPCR within 
the heteromer and, if so, whether conformational changes in both mGlu2 and 5-HT2A 
receptors were necessary for the activation of Gq/11 proteins by agonist drugs that bind to the 
mGlu2 receptor. To that aim, we investigated the effects of the mGlu2 and mGlu3 (mGlu2/3) 
receptor agonist LY379268 on Gq/11-dependent signaling in mammalian cells expressing 5-
HT2A in the presence or absence of mGlu2, as well as of mGlu2 and mGlu3 chimeric 
constructs that have different abilities to form 5-HT2A–mGlu2 heteromers. We showed that 
the presence of both 5-HT2A and mGlu2 in a heteromer was necessary for the stimulation of 
Gq/11-dependent signaling by LY379268. We also demonstrated that whereas coexpression 
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of an mGlu2 receptor with a mutant 5-HT2A receptor defective in G protein activation 
abolished LY379268-stimulated Gq/11-dependent signaling, the ability of the mGlu2 
receptor to couple to and activate Gi/o proteins was required to encode this particular 
signaling outcome. In addition, our findings define the relative structural orientation of the 
two mGlu2 protomers within an mGlu2 homodimer that affected 5-HT2A receptor–
dependent function, provide evidence for the existence of this signaling crosstalk in mouse 
frontal cortex, and unravel its functional dysregulation in terms of G protein coupling 
associated with schizophrenia.
Results
Agonists of mGlu2/3 receptors increase the intracellular Ca2+ concentration in HEK 293 
cells coexpressing mGlu2 and 5-HT2A receptors
One of the limitations of heterologous expression systems is related to the relative 
stoichiometry of the receptors and other signaling components that a cell line often does not 
natively express. Using a Xenopus oocyte heterologous expression system, we previously 
showed that the mGlu2/3 receptor agonist LY379268 cross-signals and elicits Gq/11-
dependent signaling in cells coexpressing 5-HT2A and mGlu2 receptors (24). With the goal 
of validating these observations in an independent cell line expression system, we quantified 
G protein–dependent signaling in human embryonic kidney (HEK) 293 cells expressing 
mGlu2 alone, 5-HT2A alone, or mGlu2 and 5-HT2A together. Stimulation of Gq/11 elicits a 
transient increase in the concentration of intracellular calcium ([Ca2+]i) through the inositol 
1,4,5-trisphosphate (IP3)–mediated release of Ca2+ from the endoplasmic reticulum, which 
can be detected with fluorescent calcium-sensitive dyes, such as Fura-2 (25). Cells 
transfected with equal amounts of plasmids encoding enhanced yellow fluorescent protein 
(eYFP)–tagged mGlu2 (mGlu2-eYFP), mCherry-tagged 5-HT2A (5-HT2A–mCherry), both 
mGlu2-eYFP and 5-HT2A–mCherry, or with the empty plasmid pcDNA3.1 were loaded with 
the Ca2+ indicator dye Fura-2 and sequentially exposed to 100 μM LY379268 and 10 μM 
serotonin. We scored only individual cells that expressed detectable amounts of the 
respective fluorescent proteins eYFP, mCherry or both. In cells that expressed 5-HT2A–
mCherry alone, serotonin, but not the mGlu2/3 agonist LY379268, stimulated an increase in 
[Ca2+]i (Fig. 1, A to C). As expected neither serotonin nor LY379268 had such an effect in 
cells expressing mGlu2-eYFP alone (Fig. 1, A to C). In cells coexpressing mGlu2-eYFP and 
5-HT2A–mCherry, LY379268 increased [Ca2+]i (Fig. 1, A to C). In cells transfected with 
empty plasmid or plasmid encoding mGlu2-eYFP alone, adenosine 5′-triphosphate (ATP), 
which activates endogenous Gq/11-coupled P2Y purinergic receptors (26), resulted in 
increased [Ca2+]i (fig. S1). These data suggest that the mGlu2/3 receptor agonist LY379268 
induces increases in [Ca2+]i only in individual HEK 293 cells that coexpress the mGlu2 and 
5-HT2A receptors.
To determine whether this functional crosstalk from the mGlu2 receptor that requires the 5-
HT2A receptor depends upon the absolute and relative densities of the receptors, we 
compared the increases in [Ca2+]i in HEK 293 cells transfected with equivalent amounts of 
DNA consisting of various ratios of plasmids encoding eYFP- or mCherry-tagged receptors 
or of empty plasmid (fig. S2, A and B). As was observed earlier (Fig. 1, A to C), LY379268 
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increased [Ca2+]i in cells that were transfected with plasmids encoding mGlu2-eYFP and 5-
HT2A–mCherry in a 1:1 ratio (Fig. 1D). We observed the largest effect of LY379268 on 
[Ca2+]i in cells transfected with plasmids encoding mGlu2-eYFP and 5-HT2A–mCherry in a 
1:2 ratio, whereas no increase in [Ca2+]i was observed in cells transfected with plasmids 
encoding mGlu2-eYFP and 5-HT2A–mCherry in a 1:3 ratio (Fig. 1D). As expected, a 
serotonin-dependent increase in [Ca2+]i was readily detected in cells coexpressing mGlu2-
eYFP and 5-HT2A–mCherry, regardless of the ratio of the plasmids used to transfect the 
cells (Fig. 1D). On the basis of these results, our subsequent assays were performed with 
HEK 293 cells cotransfected with plasmids encoding mGlu2-eYFP and 5-HT2A–mCherry in 
a 1:2 ratio.
Previous findings (27), including ours (28), suggested that certain agonists activate some, but 
not all, of the available signaling pathways, an effect described as “ligand bias.” We tested 
whether the effect of LY379268 on [Ca2+]i in HEK 293 cells coexpressing mGlu2-eYFP and 
5-HT2A–mCherry was shared by other mGlu2/3 receptor agonists. We assessed the effects of 
different concentrations of the mGlu2/3 receptor agonists LY379268 and LY404039, as well 
as that of the endogenous agonist L-glutamate. In individual cells coexpressing mGlu2-eYFP 
and 5-HT2A–mCherry, all three agonists led to increased [Ca2+]i (Fig. 1E, left panel, and fig. 
S3), effects that were prevented by the mGlu2/3 antagonist LY341495 (Fig. 1F). Serotonin 
stimulated increases in [Ca2+]i in cells that were cotransfected with plasmids encoding 
mGlu2-eYFP and 5-HT2A–mCherry (Fig. 1E, right panel, and fig. S3), an outcome that was 
unaffected by the presence of LY341495 (Fig. 1F).
LY379268 increases [Ca2+]i through 5-HT2A–mGlu2 heteromers
We previously demonstrated that neither the mGlu3 receptor, which is closely related to the 
mGlu2 receptor, nor the 5-HT2C receptor, which is closely related to the 5-HT2A receptor, 
was capable of forming heteromers with the 5-HT2A or mGlu2 receptors, respectively (22). 
Through experiments with a series of molecular chimeras, we showed that three residues 
located at the intracellular end of the fourth transmembrane domain (TM4) are necessary for 
the mGlu2 receptor to be assembled as a GPCR heteromer with the 5-HT2A receptor (23). 
Thus, substitution of residues Ala-6774.40, Ala-6814.44, and Ala-6854.48 in mGlu2 for 
Ser-6864.40, Phe-6904.44, and Gly-6944.48 in mGlu3 (to generate the mGlu2ΔTM4N 
chimera) substantially reduces its ability to form a complex with the 5-HT2A receptor. We 
also demonstrated previously that an mGlu2/mGlu3 chimera containing TM4 and TM5 of 
the mGlu2 receptor (mGlu3ΔTM4,5) formed a heteromer with the 5-HT2A receptor (22).
To test whether the Ca2+ signal induced by activation of the mGlu2 receptor in cells 
coexpressing the mGlu2 and 5-HT2A receptors required heteromer formation, we monitored 
LY379268-stimulated [Ca2+]i signaling in HEK 293 cells cotransfected with plasmids 
encoding 5-HT2A–mCherry and mGlu2-eYFP, mGlu3-eYFP, mGlu2ΔTM4N-eYFP, or 
mGlu3ΔTM4,5-eYFP. LY379268 stimulated [Ca2+]i release in cells co-expressing the 
mGlu2-eYFP receptor and the 5-HT2A–mCherry receptor (Fig. 1G). In contrast, LY379268 
did not stimulate [Ca2+]i release in cells coexpressing mGlu3-eYFP and 5-HT2A–mCherry 
(Fig. 1G) or in cells coexpressing mGlu2-eYFP and a C-terminally c-Myc–tagged 5-HT2C 
receptor (fig. S4). The signaling response to the mGlu2/3 agonist was absent in cells 
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coexpressing 5-HT2A–mCherry and mGlu2ΔTM4N-eYFP but was rescued in cells 
coexpressing 5-HT2A–mCherry and mGlu3ΔTM4,5-eYFP (Fig. 1G). Each of these chimeric 
constructs was expressed at the plasma membrane (fig. S5), and we determined previously 
by [3H]LY341495 binding saturation curves that their relative abundances are comparable 
(22, 23). Similarly, when expressed as homodimers, each of the mGlu2/mGlu3 chimera 
constructs facilitated Gi/o-dependent signaling (Fig. 1H). Thus, the potency and efficacy of 
LY379268-stimulated [35S]GTPγS binding were similar in plasma membrane preparations 
of cells transfected with either mGlu2-eYFP, mGlu3-eYFP, mGlu2ΔTM4N-eYFP, or 
mGlu3Δ-TM4,5-eYFP, (F 9,68 = 1.65, P > 0.05) (Fig. 1H). Together, these findings suggest 
that activation of the mGlu2 receptor stimulates increased [Ca2+]i through a molecular 
mechanism that requires the presence of both the mGlu2 and 5-HT2A receptors in a 
heteromeric complex.
A 5-HT2A receptor that activates G proteins is necessary for the increased [Ca2+]i caused 
by agonist binding to the mGlu2 receptor in 5-HT2A–mGlu2 heteromers
We tested whether functional coupling of the 5-HT2A receptor to G proteins was required for 
signaling crosstalk between the components of the 5-HT2A–mGlu2 receptor heterocomplex. 
Addition of the 5-HT2A receptor inverse agonist M100,907 (volinanserin) blocked the effect 
of both LY379268 and serotonin on Ca2+ release in cells coexpressing mGlu2-eYFP and 5-
HT2A–mCherry (Fig. 2A). As expected, however, the ability of ATP to induce an increase in 
the [Ca2+]i concentration was unaffected by M100,907 in cells coexpressing mGlu2-eYFP 
and 5-HT2A–mCherry (fig. S1B).
Considering that inverse agonists stabilize an inactivated state of the receptor (24), we next 
tested whether 5-HT2A receptor–dependent function was involved in the crosstalk 
mechanism between the components of the 5-HT2A–mGlu2 heterocomplex. Previous 
findings demonstrated that mutation of a conserved hydrophobic leucine or isoleucine in 
intracellular loop 2 (ICL2) of the Gq/11-coupled α1B-adrenergic and histamine H1 receptors 
eliminates agonist-mediated signaling but not agonist binding (14). Thus, we substituted 
Ile181 in the 5-HT2A receptor for aspartate (an I181D mutation). We found that this mutation 
in ICL2 eliminated the serotonin-stimulated increase in [Ca2+]i concentration in cells 
expressing 5-HT2A–I181D–mCherry (Fig. 2B). Furthermore, despite 5-HT2A–I181D–
mCherry and mGlu2-eYFP being in close proximity to each other as determined by flow 
cytometric analysis of fluorescence resonance energy transfer (FCM-based FRET; fig. S6, A 
and B), LY379268 did not stimulate increased [Ca2+]i (Fig. 2B). Thus, no signaling crosstalk 
was observed between mGlu2 and a 5-HT2A receptor carrying a mutation that abolishes 5-
HT2A–dependent G protein activation. ATP induced Ca2+ release in cells coexpressing 5-
HT2A–I181D–mCherry and mGlu2-eYFP (fig. S1C). 5-HT2A and 5-HT2A–I181D showed 
equivalent plasma membrane expression and densities as defined by immunocytochemical 
assays (fig. S5A) and [3H]ketanserin binding saturation curves in plasma membrane 
preparations (fig. S7A), respectively. Together with the effects of M100,907 on LY379268-
dependent Ca2+ release (Fig. 2A), these findings suggest that a 5-HT2A receptor that 
interacts with G proteins is required for the effects of the mGlu2/3 receptor agonist 
LY379268 on [Ca2+]i signaling in cells expressing 5-HT2A–mGlu2 heteromers.
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Previous findings suggested that under certain conditions, GPCRs whose canonical signaling 
pathway is mediated by Gi/o may also activate phospholipase C (PLC), the first signaling 
component downstream of Gq/11 in most experimental systems (29, 30). To test whether 
activation of Gq/11-dependent signaling was of central importance for the effects of the 
mGlu2/3 receptor agonist LY379268 in cells coexpressing 5-HT2A and mGlu2 receptors, we 
measured the ability of the selective Gq/11 inhibitor UBO-QIC (also known as FR900359) to 
prevent increased [Ca2+]i mobilization (31). We found that the effect of LY379268 on Ca2+ 
release in cells coexpressing mGlu2-eYFP and 5-HT2A–mCherry was abolished in the 
presence of UBO-QIC (Fig. 2C). The serotonin-stimulated increase in [Ca2+]i was also 
disrupted by UBO-QIC in cells coexpressing 5-HT2A–mCherry and mGlu2-eYFP (Fig. 2C). 
As expected, this inhibitor of Gq/11-dependent signaling also blocked the ATP-stimulated 
increase in [Ca2+]i in control-transfected cells (fig. S1D). The PLC-γ inhibitor U73122 
disrupted both LY379268-and serotonin-dependent Ca2+ release (Fig. 2D). U73122 also 
blocked the ATP-stimulated increase in [Ca2+]i in control-transfected cells (fig. S1E). 
Together, these results corroborate the idea that the effect of the mGlu2/3 agonist LY379268 
on Ca2+ release in cells coexpressing 5-HT2A and mGlu2 heteromers is Gq/11-dependent.
An mGlu2 receptor that activates G proteins is necessary for the increase in [Ca2+]i 
induced by agonist binding to mGlu2 through the 5-HT2A–mGlu2 heterocomplex
To further clarify how agonist binding to the mGlu2 component of the 5-HT2A–mGlu2 
heteromer led to Ca2+ signaling, we introduced the F756S mutation into the ICL3 of mGlu2, 
which abolishes G protein activation (32). We first confirmed that the plasma membrane 
abundance (fig. S5A) and binding properties of mGlu2-F756S (fig. S7B) were unaffected. 
Our data also showed that mGlu2-F756S–eYFP and 5-HT2A–mCherry were found in close 
proximity to each other (fig. S6, C and D). However, LY379268 did not induce Ca2+ release 
in cells coexpressing mGlu2-F756S–eYFP and 5-HT2A–mCherry (Fig. 2E). Serotonin 
induced an increase in [Ca2+]i in cells coexpressing mGlu2-F756S–eYFP and 5-HT2A–
mCherry (Fig. 2E). These data suggest that an mGlu2 receptor that can activate Gi/o proteins 
is necessary for the LY379268-mediated increase in [Ca2+]i. An alternative, although not 
mutually exclusive, explanation of these results is that mGlu2-F756S affects the 
conformational properties (and hence the signaling) of the 5-HT2A–mGlu2 heteromer 
through a mechanism that does not require the activation of Gi/o proteins. To directly 
examine whether coupling to Gi/o was necessary for the effect of LY379268 on Ca2+ release 
in cells expressing mGlu2 and 5-HT2A heteromers, we investigated the effect of pertussis 
toxin (PTX), which induces the adenosine diphosphate (ADP) ribosylation of the α subunit 
of heterotrimeric Gi/o proteins, locking the α subunit into a GDP-bound inactive state; thus, 
PTX can disrupt the function of both the α and βγ subunits of Gi/o proteins. LY379268 failed 
to increase [Ca2+]i in PTX-treated HEK 293 cells coexpressing mGlu2-eYFP and 5-HT2A–
mCherry (Fig. 2F), a result that differs from that previously obtained from experiments with 
oocytes (24). As expected, PTX did not affect serotonin-induced Ca2+ release in cells 
coexpressing 5-HT2A–mCherry and mGlu2-eYFP (Fig. 2F). Together with our findings from 
experiments with mGlu2-F756S, these results suggest that coupling to and activation of Gi/o 
proteins is necessary for the 5-HT2A–mGlu2 heteromer–dependent effects of the mGlu2/3 
agonist LY379268.
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The effects of LY379268 on Ca2+ release in cells expressing the 5-HT2A–mGlu2 
heterocomplex depend on Gαi/o but not on Gβγ
To gain insight into the crosstalk mechanism between the mGlu2 and 5-HT2A receptors, we 
directly compared the effects of NF023, which selectively inhibits the α subunit of Gi/o 
proteins (33), with those of a Gβγ-blocking peptide (MPS phosducin-like protein C-
terminus) (34). LY379268 did not induce Ca2+ release in cells coexpressing mGlu2-eYFP 
and 5-HT2A–mCherry in the presence of NF023 (Fig. 2G). On the contrary, MPS had no 
effect on the LY379268-dependent increase in [Ca2+]i in cells coexpressing mGlu2-eYFP 
and 5-HT2A–mCherry (Fig. 2H). Neither NF023 nor MPS disrupted serotonin-stimulated 
Ca2+ release in cells expressing both 5-HT2A–mCherry and mGlu2-eYFP (Fig. 2, G and H). 
As an internal control, we next asked whether MPS disrupted Gβγ-dependent activity in 
HEK 293 cells. GIRK channels are sensitive to the Gβγ subunits of Gi/o proteins (35). As 
expected, the presence in HEK 293 cells of the nonhydrolyzable GTP analog GTPγS, which 
induces the constitutive activation of heterotrimeric G proteins, led to stimulation of GIRK 
currents (Fig. 2, I and J). This effect of GTPγS on Gβγ-dependent activity was prevented in 
the presence of the Gβγ-blocking peptide MPS (Fig. 2, I and J). These findings demonstrate 
that whereas the Gβγ-blocking peptide MPS has repressive effects on Gβγ-dependent 
channel activity in HEK 293 cells, the presence of MPS did not affect the impact of 
LY379268 on Ca2+ release in cells coexpressing mGlu2-eYFP and 5-HT2A–mCherry.
A functionally active mGlu2 homodimer rescues the increased [Ca2+]i induced by 
LY379268 through the 5-HT2A–mGlu2 heterocomplex
To explore further the specific role of the mGlu2 component in the effect on Ca2+ release, 
we tested any possible functional complementation between two nonfunctional mGlu2 
protomers and the 5-HT2A receptor (Fig. 2, K and L). We combined the use of bimolecular 
fluorescence complementation (BiFC) (36) and mGlu2 constructs carrying mutations in lobe 
II of the Venus flytrap domain (Y216A, D295A; YADA) (37), which abolished ligand 
binding (fig. S7B) and receptor function (Fig. 2L), without disrupting plasma membrane 
expression (fig. S5A), or mutations in ICL3 (F756S), which abolished G protein activation 
(Fig. 2L). We first validated that the effect of LY379268 on increased [Ca2+]i was absent in 
cells coexpressing Y216A-D295A–mGlu2-eYFP (YADA-mGlu2-eYFP) and 5-HT2A–
mCherry (Fig. 2K), even though both constructs were found in close proximity to each other, 
as defined by FCM-based FRET (fig. S6, C and D). Similarly, and as expected on the basis 
of previous findings that showed that mGlu2 receptors form stable homodimers (38), BiFC 
was observed in cells coexpressing mGlu2 with either the N-terminal 172–amino acid 
fragment or the C-terminal 67–amino acid fragment of mCitrine (mCi-N172 and mCi-C67, 
respectively) (fig. S5, B and C). We also confirmed that the mGlu2/3 agonist LY379268 
stimulated Gi/o-dependent signaling in cells coexpressing YADA–mGlu2–mCi-N172 and 
mGlu2-F756S–mCi-C67 (Fig. 2L). Thus, linear versus nonlinear regression analysis showed 
that LY379268-stimulated [35S]GTPγS binding in cells expressing mGlu2-eYFP could be fit 
preferentially by a concentration-response curve, whereas linear regression analysis 
provided the best fit to LY379268-stimulated [35S]GTPγS binding in cells expressing either 
YADA-mGlu2-eYFP alone or mGlu2-F756S–eYFP alone, as assessed by F test (Fig. 2L). 
Linear versus nonlinear regression analysis showed that LY379268-stimulated [35S]GTPγS 
binding in cells coexpressing YADA–mGlu2–mCi-N172 and mGlu2-F756S–mCi-C67 can 
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be fit preferentially by a concentration-response curve, as assessed by F test (Fig. 2L). 
Additionally, the potency and efficacy of LY379268 stimulating [35S]GTPγS binding were 
similar in plasma membrane preparations of cells expressing mGlu2-eYFP or coexpressing 
YADA–mGlu2–mCi-N172 and mGlu2-F756S–mCi-C67 (F3,46 = 0.40, P > 0.05) (Fig. 2E). 
Note that the effect of LY379268 on Ca2+ release was rescued in cells coexpressing YADA–
mGlu2–mCi-N172 and mGlu2-F756S–mCi-C67 together with 5-HT2A–mCherry (Fig. 2K). 
Serotonin induced increases in [Ca2+]i in cells coexpressing 5-HT2A–mCherry with mGlu2-
eYFP, YADA-mGlu2-eYFP, or YADA–mGlu2–mCi-N172 and mGlu2-F756S–mCi-C67 but 
not in control-transfected cells (Fig. 2K). These findings suggest that a fully functional 
mGlu2 homodimeric receptor complex and its intrinsic G protein coupling properties are 
fundamental for this component of the 5-HT2A–mGlu2 heteromeric receptor complex to 
crosstalk with the 5-HT2A component.
Characterization of the relative orientation of the two mGlu2 protomers that affect 5-HT2A 
receptor–dependent function
The data thus far suggest that the expression of an mGlu2 mutant receptor that binds to 
orthosteric agonists (that is, an agonist that binds to the same binding site on the GPCR as 
the endogenous agonist), but does not activate G proteins, together with an mGlu2 mutant 
that does not bind to ligands, but retains intact the regions involved in G protein coupling, 
rescues the Gq/11-dependent signaling events induced by the mGlu2/3 agonist LY379268 
through the 5-HT2A–mGlu2 heteromer. These results, together with our previous 
demonstration that the intracellular end of TM4 of mGlu2 is necessary to form a protein 
complex with the 5-HT2A receptor (23), led us to explore the relative location of the mGlu2 
protomer that needs to make contact with Gi/o to enable crosstalk with 5-HT2A receptor. We 
attempted to answer this question by combining mGlu2/mGlu3 chimeric constructs that 
disrupt 5-HT2A–mGlu2 heteromer formation with mutations in either the Venus flytrap 
module or the ICL3 of the mGlu2 receptor, which specifically affect ligand binding or G 
protein coupling, respectively. We hypothesized that if the mGlu2 protomer that directly 
makes contact with the 5-HT2A receptor is fundamental for interacting with Gi/o proteins, 
then the effect of the mGlu2/3 agonist LY379268 on Ca2+ release through the 5-HT2A–
mGlu2 heteromer would be disrupted in cells coexpressing YADA–mGlu2ΔTM4N–mCi-
N172 (an mGlu2 mutant that cannot bind to orthosteric agonists or form 5-HT2A–mGlu2 
heteromers) and mGlu2-F756S–mCi-C67 (an mGlu2 mutant that does not activate Gi/o 
proteins) together with 5-HT2A–mCherry (Fig. 3A). Alternatively, if the distal mGlu2 
protomer is necessary for Gi/o protein coupling, then the effect of the mGlu2/3 agonist 
LY379268 on Ca2+ release stimulated by 5-HT2A–mGlu2 heteromers would be disrupted in 
cells coexpressing YADA–mGlu2–mCi-N172 (an mGlu2 mutant that cannot bind to 
orthosteric agonists) and mGlu2ΔTM4N-F756S–mCi-C67 (an mGlu2 mutant that cannot 
activate Gi/o proteins or form 5-HT2A–mGlu2 heteromers) together with 5-HT2A–mCherry 
(Fig. 3B). We found that LY379268 induced Ca2+ release in cells coexpressing YADA–
mGlu2ΔTM4N–mCi-N172 and mGlu2-F756S–mCi-C67 with 5-HT2A–mCherry (Fig. 3, A 
and C), but not in cells coexpressing YADA–mGlu2–mCi-N172 and mGlu2ΔTM4N-F756S–
mCi-C67 with 5-HT2A–mCherry (Fig. 3, B and C).
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Additional controls included plasma membrane expression (figs. S5, B and C, and S7B) and 
the presence of G protein coupling in cells coexpressing either YADA–mGlu2ΔTM4N–mCi-
N172 and mGlu2-F756S–mCi-C67 or YADA–mGlu2–mCi-N172 and mGlu2ΔTM4N-
F756S–mCi-C67 constructs (Fig. 3D). Thus, the potency and efficacy of LY379268 
stimulating [35S]GTPγS binding were similar in plasma membrane preparations of cells 
cotransfected with YADA–mGlu2ΔTM4N–mCi-N172 and mGlu2-F756S–mCi-C67 as 
compared to those obtained in cells co-transfected with YADA–mGlu2–mCi-N172 and 
mGlu2ΔTM4N-F756S–mCi-C67 (F3,130 = 0.49, P > 0.05) (Fig. 3D). These data suggest that 
the mGlu2 promoter that binds to LY379268 must have an intact TM4 with which to 
communicate with 5-HT2A. The data also suggest that Gi/o protein coupling to the distal 
mGlu2 protomer within the 5-HT2A–mGlu2 heteromeric receptor complex is necessary to 
induce Ca2+ release through Gq/11 proteins.
Computational modeling and experimental evidence reveal higher-order oligomerization
Previous studies suggested that family A GPCRs form homodimers or higher-order 
oligomers in live cells (8). Thus, we tested whether at least two 5-HT2A receptor molecules 
formed part of the 5-HT2A–mGlu2 heteromeric complex. We established in our experimental 
system the conditions to monitor sequential 3-FRET and used this biophysical approach to 
detect oligomeric complexes in single live cells. Three fluorescent proteins(Cerulean, 
mCitrine, and mCherry) were selected on the basis of the overlaps of the emission 
wavelengths of the donors with the excitation of wavelengths of the acceptors (see Materials 
and Methods). Additional assays were performed with the nonfluorescent variant of 
mCitrine (Y67C). The incorporation of an N-terminal c-Myc epitope tag into the construct 
enabled the immunological detection of 5-HT2A–mCitrine-Y67C and showed that it had the 
same pattern of distribution as did 5-HT2A–mCitrine (fig. S8). Coexpression of 5-HT2A–
Cerulean, 5-HT2A–mCitrine, and mGlu2-Cherry followed by excitation at 425 nm resulted 
in FRET between Cerulean and mCherry (Fig. 4A) and between Cerulean and mCitrine (Fig. 
4B). Excitation of cells with 495-nm light resulted in FRET between mCitrine and mCherry 
(Fig. 4C). When 5-HT2A–Cerulean, 5-HT2A–mCitrine-Y67C, and mGlu2-mCherry were 
expressed together, the FRET between Citrine and mCherry was almost eliminated (Fig. 
4A). Because FRET signals were normalized to take into account any variation in the 
abundances of the different constructs (see Materials and Methods), this suggests that the 
difference in the FRET signal between Cerulean and mCherry in live cells coexpressing 5-
HT2A–Cerulean, 5-HT2A–mCitrine, and mGlu2-Cherry compared to that observed in cells 
coexpressing 5-HT2A–Cerulean, 5-HT2A–mCitrine-Y67C, and mGlu2-mCher-ry likely 
corresponds to sequential FRET signal from Cerulean to mCitrine and then to mCherry. 
Together, these studies suggest that at least a portion of these receptors in cells were within 
an oligomeric complex in which the components were at distances that enabled FRET.
We next focused our attention on the relative location of the 5-HT2A receptor molecules 
within the 5-HT2A–mGlu2 heteromeric complex. Much evidence indicates that TM1 and 
TM4 contribute to symmetrical interfaces in homomeric complexes of family A GPCRs (8). 
As discussed earlier, we previously identified that TM4 of the mGlu2 receptor is necessary 
for it to form heteromers with the 5-HT2A receptor (23). With the goal of defining the TM 
domains of 5-HT2A that are responsible for the formation of 5-HT2A–mGlu2 heteromers, we 
Moreno et al. Page 10
Sci Signal. Author manuscript; available in PMC 2017 January 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
performed immunoprecipitation assays with antibodies against the c-Myc tag in plasma 
membrane preparations of HEK 293 cells transfected with plasmid encoding the 
hemagglutinin (HA)–tagged form of the mGlu2 receptor alone or together with plasmid 
encoding a c-Myc–tagged form of the 5-HT2A receptor or an equivalent c-Myc–tagged 5-
HT2A/5-HT2C receptor chimera (Fig. 4, D and E). Similar to a previous report (23), when 
lysates of cells coexpressing HA-mGlu2 and c-Myc–5-HT2A were subjected to 
immunoprecipitation with anti–c-Myc antibodies, we observed coimmunoprecipitation of a 
band that was detectable with an anti-HA antibody, which did not occur when 
coimmunoprecipitations were performed with cells expressing either HA-mGlu2 or c-Myc–
5-HT2A alone or when plasma membrane preparations from cells expressing either the HA- 
or the c-Myc–tagged forms of the receptors were combined before immunoprecipitation was 
performed (Fig. 4D). Furthermore, immunodetection of an HA-containing protein was not 
observed when lysates of cells coexpressing 5-HT2C–c-Myc and HA-mGlu2 were subjected 
to immunoprecipitation with anti–c-Myc antibody (Fig. 4D). Such observations are 
consistent with the formation of receptor complexes between the tagged forms of mGlu2 and 
5-HT2A receptors but not 5-HT2C receptors.
The differences in the capacity of the 5-HT2A and 5-HT2C receptors to interact with the 
mGlu2 (see also fig. S4) and their close sequence similarity provided the basis for 
identifying the specific regions of the 5-HT2A receptor that were responsible for the 
formation of 5-HT2A–mGlu2 heteromers. A study of molecular chimeras of 5-HT2A and 5-
HT2C receptors demonstrated that TM4, but not TM1, of the 5-HT2A receptor was necessary 
for the formation of a complex with the mGlu2 receptor (Fig. 4E and fig. S5D). Together 
with our earlier 3-FRET data that revealed higher-order heteromerization (Fig. 4, A to C) 
and our findings focused on functional complementation between two nonfunctional mGlu2 
protomers (Fig. 3), these results suggest that the mGlu2 protomer located distally from the 
5-HT2A homomer within the 5-HT2A–mGlu2 heteromer was necessary to activate Gi/o 
proteins, which consequently led to the transactivation of 5-HT2A. We built a homology 
model of the 5-HT2A–mGlu2 heteromer (see Materials and Methods) together with Gi/o and 
Gq/11 proteins that is consistent with our experimental results (Fig. 5).
Gq/11-dependent signaling in response to the activation of mGlu2 requires the presence of 
5-HT2A receptors in the mouse frontal cortex
A key question in validating the biological relevance of GPCR heteromeric complexes is 
whether this structural arrangement exists and functions in native tissue. Our previous work 
demonstrated that immunoprecipitation experiments performed with anti–5-HT2A antibodies 
and plasma membrane preparations of mouse frontal cortex results in 
coimmunoprecipitation of anti-mGlu2 immunoreactivity (23). Nevertheless, it is unclear 
whether 5-HT2A and mGlu2 receptors form part of the same protein complex in presynaptic 
or postsynaptic cortical membranes. To study the potential contribution of presynaptic and 
postsynaptic 5-HT2A and mGlu2 receptors to signaling crosstalk, we performed sub-cellular 
fractionations to purify fractions enriched in presynaptic active zone (PAZ) and postsynaptic 
density (PSD) proteins. We confirmed the enrichment of PSD proteins (PSD-95) and the 
absence of detectable PAZ proteins (syntaxin-1) in the PSD fraction, as well as the absence 
of detectable PSD proteins and the enrichment of PAZ proteins in the PAZ fraction of the 
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mouse frontal cortex (Fig. 6A). Furthermore, 5-HT2A was detected only in the PSD, whereas 
mGlu2 was detected in both the PSD and PAZ fractions (Fig. 6B). Together with our 
previous findings showing coimmunoprecipitation of cortical 5-HT2A and mGlu2 receptors 
(24), these data suggest that 5-HT2A and mGlu2 may form a protein complex at the PSD in 
the mouse frontal cortex.
To further explore whether 5-HT2A and mGlu2 receptors exhibited crosstalk and affected G 
protein coupling in native tissue, we performed [35S]GTPγS binding assays followed by 
immunoprecipitation with antibodies against Gαi1,2,3 proteins or Gαq/11 proteins in plasma 
membrane preparations from the mouse frontal cortex. Activation of Gαi1,2,3 and Gαq/11 
was markedly induced by LY379268 in the frontal cortex of wild-type mice (Fig. 6, C to F), 
effects that were reduced in the presence of the mGlu2/3 receptor antagonist LY341495 (Fig. 
6, C to F). We also found that the ability of LY379268 to activate Gi1,2,3 and Gαq/11 was 
absent in the frontal cortex of mGlu2−/− mice (Fig. 6, C and D). Further-more, when the 
coupling of mGlu2 to G proteins was tested in frontal cortex of 5HT2A−/− mice, LY379268 
stimulated the activation of Gi1,2,3 proteins (Fig. 6E), but the LY379268-dependent 
activation of Gq/11 proteins was substantially reduced (Fig. 6F). These data suggest that the 
canonical coupling of mGlu2 receptors to Gi1,2,3 proteins is unaffected by the loss of the 5-
HT2A receptor but that its coupling to Gq/11 proteins requires the presence of the 5-HT2A 
receptor in the mouse frontal cortex.
Alterations in G protein coupling through 5-HT2A–mGlu2 heteromers in postmortem frontal 
cortex tissue from schizophrenic subjects
A previous study suggested that drugs that activate the mGlu2 receptor may represent an 
approach to treat schizophrenia (39). We previously found that the density of 5-HT2A 
receptors in the frontal cortex of postmortem schizophrenic subjects, as defined by 
[3H]ketanserin binding saturation curves, is increased compared to that in the frontal cortex 
of normal subjects, whereas the density of the mGlu2 receptor, as defined by [3H]LY341495 
binding saturation curves and quantitative real-time polymerase chain reaction (PCR) assays, 
is reduced, a pattern that could predispose patients to psychosis (22, 23, 40, 41). Here, we 
investigated in postmortem frontal cortex samples of schizophrenic subjects and individually 
matched controls (table S1) the pattern of G protein coupling that, on the basis of our 
findings in heterologous expression systems and mouse frontal cortex, requires expression of 
5-HT2A and mGlu2 heteromers. We performed [35S]GTPγS binding assays followed by 
immunoprecipitation with antibodies against Gαi1,2,3 or Gαq/11. Activation of Gαi1,2,3 
proteins was markedly induced by LY379268 in plasma membrane preparations of 
postmortem human frontal cortex in a concentration-dependent manner (Fig. 7A). 
Furthermore, the extent of activation of Gq/11 proteins by LY379268 was substantially 
reduced in frontal cortex preparations from schizophrenic subjects compared to that in the 
frontal cortex of controls (Fig. 7B), whereas the LY379268-dependent activation of Gαi1,2,3 
proteins was unaffected (Fig. 7A and table S2). The ability of LY379268 to activate Gαi1,2,3 
and Gαq/11 proteins was reduced by the mGlu2/3 receptor antagonist LY341495 (Fig. 7, A 
and B).
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Discussion
Previous studies provided mechanistic insights into functional complementation between 
protomers of family A and family C GPCRs in homomeric and homodimeric complexes, 
including the homomeric α1B-adrenoreceptor (26), the homomeric dopamine D2 receptor 
(17), and the homodimeric mGlu1 receptor (37, 42). However, whereas functional analysis 
has demonstrated that GPCR heteromers behave differently both in heterologous expression 
systems and in animal models as compared to GPCR homomers (8), understanding the 
precise structural determinants underlying how individual protomers within a GPCR 
heteromeric complex crosstalk with each other has been a major biochemical challenge. We 
previously showed that the Gq/11-coupled 5-HT2A receptor and the Gi/o-coupled mGlu2 
receptor form a GPCR heteromer through which ligands that bind to the 5-HT2A receptor 
modulate Gi/o-dependent signaling, whereas ligands that bind to the mGlu2 receptor 
modulate Gq/11-dependent signaling (22, 24). Here, we reported on the crosstalk mechanism 
between the components of the 5-HT2A–mGlu2 heteromer. Through an experimental 
approach to dissect the various components that contribute to the response induced by 
activation of the 5-HT2A–mGlu2 heteromer, we showed that functional coupling of the 
mGlu2 receptor to Gi/o proteins was necessary for mGlu2/3 receptor agonists to crosstalk 
through the heteromeric receptor complex, consequently stimulating Gq/11-dependent 
signaling. We also delineated the relative location of the mGlu2 protomer within the mGlu2 
homodimer that needs to couple to Gi/o proteins to transactivate the 5-HT2A receptor. 
Because some of these findings were validated in mouse and human frontal cortex, the 
proposed mechanistic explanation for crosstalk between the 5-HT2A and mGlu2 receptors 
may be generalizable to other experimental systems and to native tissues. The translational 
potential of these results is substantiated by our findings that the activation of Gq/11 
signaling by the mGlu2/3 agonist LY379268 was dysregulated in the postmortem frontal 
cortex of schizophrenic subjects.
A key conclusion drawn from our experiments with mGlu2 receptors with mutations in ICL3 
and the blockade of Gi/o protein coupling by PTX is that functional coupling to Gi/o proteins 
was necessary for drugs that activate the mGlu2 receptor to stimulate increased [Ca2+]i 
concentrations in cells coexpressing 5-HT2A and mGlu2 receptors. Previous findings in live 
cells are consistent with the hypothesis that, for certain GPCR systems, the minimal 
signaling unit necessary to activate a single G protein is composed of at least two GPCR 
protomers (17, 37). Additionally, a study based on the generation of nanodiscs containing 
either one or two GPCR molecules indicates that only a single protomer interacts with the G 
protein (43). Our data further extend these findings and suggest that the coupling of the 
mGlu2 receptor to Gi/o proteins is necessary for drugs that activate mGlu2 to elicit Gq/11-
dependent signaling when this glutamate receptor is in close proximity to the 5-HT2A 
receptor. This effect of agonist activation of mGlu2 on increases in the concentration of 
[Ca2+]i in cells expressing mGlu2 and 5-HT2A heteromers also demonstrates that the binding 
of orthosteric agonists to the Gi/o-coupled mGlu2 receptor initiates structural rearrangements 
that are consequently transmitted to the Gq/11-coupled 5-HT2A receptor. Thus, our findings 
showed that either a single point mutation in ICL2 of the 5-HT2A receptor, which disrupts 
receptor–G protein coupling without having major effects on the proximity between the 5-
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HT2A and mGlu2 receptors, or the selective Gq/11 inhibitor UBO-QIC abolishes the ability 
of mGlu2 to elicit calcium signaling in response to LY379268 through the 5-HT2A–mGlu2 
heteromer. Further experiments analyzing single 5-HT2A–mGlu2 heteromers will be needed 
to shed light on whether Gi/o and Gq/11 proteins simultaneously or sequentially couple to the 
GPCR heteromer. To achieve this, it will be crucial to incorporate knowledge gained from 
crystallographic studies that have provided convincing evidence that the TM7 domain of 
mGlu1 forms a parallel homodimer with an interface mediated mainly through TM1 (44), as 
well as from in vitro assays focused on the dynamics of the mGlu2 homodimeric interface 
during receptor activation (45).
Although homodimerization is a requirement for the ability of mGlu receptors to couple to 
and activate G proteins in live cells (37), the exact location of the mGlu2 protomer within 
the 5-HT2A–mGlu2 heteromer that needs to contact the Gi/o protein to crosstalk with the 5-
HT2A receptor was unclear. Here, we took advantage of the trans-protomer allosteric 
regulation between mGlu2 and 5-HT2A to determine to which of the two mGlu2 protomers 
the Gi/o heterotrimer could be docked. We measured the effect of the mGlu2/3 receptor 
agonist LY379268 on Ca2+ release in HEK 293 expressing two mutant mGlu2 protomers, 
one of which binds to orthosteric agonists but cannot activate G proteins, whereas the other 
cannot bind to orthosteric agonists but can still interact with G proteins and the 5-HT2A 
receptor. Although previous computer modeling studies proposed the relative location of the 
heterotrimeric G protein with respect to a higher-order family A GPCR homomer (9), our 
findings provide insights into the structural mechanism underlying G protein coupling 
crosstalk between the components of the 5-HT2A–mGlu2 heteromer. Thus, these data 
suggest that the coupling of Gi/o to the distal mGlu2 protomer is required for the activation 
of Gq/11-dependent signaling by mGlu2/3 agonists through the receptor heteromer in live 
cells.
We and others have confirmed in HEK 293 cells that at least a fraction of the populations of 
mGlu2 and 5-HT2A receptors constitute part of the same protein complex, as defined by 
coimmunoprecipitation assays (23, 46). Furthermore, both receptors are found in close 
proximity to each other as defined independently by biophysical assays such as BRET 
(bioluminescence resonance energy transfer) (22), FRET (23), antibody-based time-resolved 
FRET (TR-FRET) (46), and a combination of TR-FRET and the SNAP-tag approach (47). 
Previous data demonstrated that functional crosstalk between particular subtypes of Gi/o- 
and Gq/11-coupled receptors does not require both receptors to be proximal to each other 
(46). Thus, it was reported that activation of the Gi/o-coupled GABAB receptor enhances the 
mGlu1 receptor–mediated activation of Gq/11 proteins through a mechanism that does not 
require any physical interaction between the GABAB and mGlu1 receptors (46). It was also 
established that this crosstalk between GABAB and mGlu1 receptors is mediated through the 
Gβγ subunit of the Gi/o proteins that couple to the GABAB receptor (46). Through 
experiments with wild-type 5-HT2C and mGlu3 receptors, as well as with mGlu2/mGlu3 
chimeric constructs that differed in their ability to form heteromers with 5-HT2A, our 
previous and current results provide evidence for the existence of a crosstalk mechanism 
between these two receptors that requires their physical association (22–24). Additionally, 
our findings suggest that Gαi/o, but not the Gβγ subunit of Gi/o proteins released after 
activation of the mGlu2 receptor, is necessary for the crosstalk between mGlu2 and the 
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Gq/11-coupled 5-HT2A receptor. This represents an alternative crosstalk mechanism between 
coexpressed receptors that are coupled to different G proteins, which is supported by 
findings demonstrating that agonist alone does not fully stabilize the active conformation of 
the β2-adrenergic receptor (48). Further work is needed to define the biophysical and cellular 
trafficking processes that modulate heteromeric assembly of the 5-HT2A and mGlu2 
receptors and how these events, as well as signaling crosstalk and com-partmentalization in 
membrane microdomains, are affected by their absolute and relative abundances. Our data 
suggesting the functional interaction between the components of the 5-HT2A–mGlu2 
heteromer in the mouse and human frontal cortex provide an insight into the molecular basis 
by which these two receptors interact in native tissue. However, the use of different 
experimental approaches used in the different studies may provide an explanation for the 
absence of functional and pharmacological differences previously observed between cells 
expressing 5-HT2A alone, mGlu2 alone, or 5-HT2A and mGlu2 together (47).
In this context, one of the limitations of experiments performed in heterologous expression 
systems relates to the absolute and relative abundances of each receptor and whether 
findings from these in vitro experiments can be validated in native tissue and whole animal 
models. The experiments that we performed with HEK 293 cell lines were consistent with 
those performed with Xenopus oocytes (24). For example, LY379268 stimulated Gq/11-
dependent signaling in cells expressing mGlu2 and 5-HT2A receptors as a GPCR heteromer, 
and the relative ratio of GPCR protomers in the heteromeric complex was critical for the 
efficiency of its signaling crosstalk (24). However, there were also differences between the 
two experimental systems, such as the effects of PTX on the ability of mGlu2 to initiate 
crosstalk (24). Although the reasons underlying the differences in the two systems need to 
be further explored, the major conclusions from both sets of experimental conditions are 
consistent and applicable to native tissues. Similarly, although our previous work 
demonstrated that the activation of 5-HT2A receptors by hallucinogens stimulates both 
Gq/11- and Gi/o-dependent signaling in cells expressing the 5-HT2A–mGlu2 heteromer (22), 
detailed structural information about this crosstalk remains to be determined. We are also 
generating HEK 293 cell lines that stably coexpress mGlu2 and 5-HT2A receptors at 
different relative abundances to define the basic mechanisms that govern the formation and 
function of receptor heteromers.
The frontal cortex is a region of the brain that is involved in critical processes, such as 
sensorimotor gating, cognition, and perception. Previous data suggested that the activation of 
mGlu2 autoreceptors mediates the presynaptic effects of mGlu2/3 receptor agonists in 
suppressing the electrophysiological effects of hallucinogenic 5-HT2A receptor agonists 
recorded in postsynaptic cortical pyramidal neurons (49, 50). Our finding that 5-HT2A and 
mGlu2 receptors are likely coexpressed as heteromers complex at the PSD in the cerebral 
cortex is not mutually exclusive with these findings. Our data, however, provide additional 
evidence that, together with previous observations that demonstrated coimmunoprecipitation 
in mouse (24) and human (22) frontal cortex and the physical proximity of 5-HT2A and 
mGlu2 receptors at cortical synaptic junctions as determined by electron microscopy (23), 
support the existence of an alternative pathway through which these two receptor subtypes 
crosstalk in the central nervous system.
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Although it is not without controversy (51, 52), preclinical and clinical studies suggest that 
the activation of mGlu2 by orthosteric mGlu2/3 agonists or allosteric mGlu2 agonists 
represents a new approach to treat schizophrenia and other psychotic disorders (39, 53–55). 
Through mouse models of psychosis, we showed that the expression of the 5-HT2A receptor 
is at least in part necessary for the mGlu2-dependent antipsychotic-like behavioral effects of 
the mGlu2/3 receptor agonist LY379268 (24). Given that we showed that the activation of 
Gq/11 signaling by LY379268 was substantially reduced in the frontal cortex of 5-HT2A 
knockout mice compared to that in wild-type mice, the selective reduction in the LY379268-
dependent activation of Gq/11 coupling in frontal cortex of schizophrenic subjects suggests 
that alterations in signaling processes through the 5-HT2A–mGlu2 heteromeric receptor 
complex may be involved in some of the psychotic symptoms in schizophrenia patients. In 
addition, considering that chronic treatment with atypical antipsychotic drugs epigenetically 
represses the promoter activity of the mGlu2 (Grm2) gene in mouse and human frontal 
cortex through a molecular mechanism that requires 5-HT2A receptor–dependent signaling 
(40), our current findings that suggest that the pattern of G protein coupling is affected by 
the organization of 5-HT2A and mGlu2 receptors into heteromers may provide an 
explanation for why schizophrenia patients previously treated chronically with atypical anti-
psychotic drugs fail to respond to treatment with the mGlu2/3 receptor agonist 
pomaglumetad (LY2140023 prodrug of LY404039). This notion has been supported by 
clinical testing in schizophrenia patients (56).
In conclusion, we found that functional coupling of Gi/o proteins to the mGlu2 protomer 
distal from the 5-HT2A receptor is required for the mGlu2 component of the 5-HT2A–mGlu2 
heteromeric receptor complex to crosstalk with the 5-HT2A receptor and consequently 
activate Gq/11-dependent signaling and Ca2+ release in live mammalian cells. These findings 
extend our understanding of the structural changes that underlie the pharmacology and 
function of GPCR heteromers and could be relevant for the development of new compounds 
to treat schizophrenia.
Materials and Methods
Drugs
5-Hydroxytryptamine hydrochloride (serotonin hydrochloride; 5-HT), GTPγS, and PTX 
were purchased from Sigma-Aldrich. (1R,4R,5S,6R)-4-Amino-2-
oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), (2S)-2-amino-2-[(1S,2S)-2-
carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495), methysergide, L-
glutamic acid, U73122, and NF023 were obtained from Tocris Bioscience. (1R,4S,5S,6S)-4-
[[(2S)-2-Amino-4-(methylthio)-1-oxobutyl]amino]-2-thiabicyclo[3.1.0]hexane-4,6-
dicarboxylic acid 2,2-dioxide (LY404039) was obtained from Selleckchem. The Gβγ-
blocking peptide (MPS phosducin-like protein C-terminus: 
AAVALLPAVLLALLAVTDQLGEDFFAVDLEAFLQEFGLLPEKE) was obtained from 
AnaSpec. UBO-QIC (also known as FR900359) was purchased from the Institute of 
Pharmaceutical Biology, University of Bonn. M100,907 (volinanserin) was obtained from 
Sanofi. [3H]Ketanserin and [35S]GTPγS were obtained from PerkinElmer Life and 
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Analytical Sciences Inc. [H]LY341495 was purchased from American Radiolabeled 
Chemicals Inc. All other chemicals were obtained from standard sources.
Plasmid construction
All PCR assays were performed with PfuUltra Hotstart DNA Polymerase (Stratagene) in a 
Mastercycler Ep Gradient Auto thermal cycler (Eppendorf). Cycling conditions were 30 
cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min/kb of amplicon, with an initial 
denaturation/activation step of 94°C for 2 min and a final extension step of 72°C for 7 min. 
The following constructs have previously been described: pcDNA3.1–c-Myc–5-HT2A–
mCherry, pcDNA3.1-HA-mGlu2-eYFP, pcDNA3.1-HA-mGlu3-eYFP, pcDNA3.1-HA-
mGlu2ΔTM4N-eYFP, and pcDNA3.1-HA-mGlu3ΔTM4,5-eYFP (22, 23). Introduction of 
the mutation I181D into the ICL2 of 5-HT2A, the mutation F756S into the ICL3 of mGlu2, 
and the mutations Y216A and D295A into the binding pocket of mGlu2 were performed 
with the QuikChange II Site Directed Mutagenesis Kit according to the manufacturer's 
protocol (Stratagene). All of the constructs were confirmed by DNA sequencing. To generate 
the C-terminally c-Myc-tagged form of wild-type human 5-HT2C, a PCR fragment was 
obtained using pcDNA3.1-5-HT2C from the cDNA Resource Center (Missouri University of 
Science and Technology) as a template and the primers h5-HT2C–Bmg BI/S (5′-
AACACGACGTGCGTGCTCAACG-3′) and c-Myc-h5-HT2C–Xba I/A (5′-
TCTAGATCACAGATCTTCTTCAGAAATAAGTTTTTGTTCCACACTGCTAATCCTTTC
GC-3′). The PCR product was digested with Bmg BI and Xba I and subcloned into the same 
restriction sites of pcDNA3.1–5-HT2C. To generate the chimeric human 5-HT2A with TM1 
from human 5-HT2C, we used PCR-directed mutagenesis. Two overlapping PCR fragments 
were obtained using pcDNA3.1–c-Myc–5-HT2A as a template and the primers h5-HT2C–
TM1/S (5′-
GGGGTACAAAACTGGCCAGCACTTTCAATCGTCATCATAATAATCATGACAATAGG
TGGCAACATCCTTGTGATCATGGCAGTAAGCATGGAGAAAAAGCTGCAGAATGCC
ACC-3′) and h5-HT2C –TM1/A (5′-
CATGCTTACTGCCATGATCACAAGGATGTTGCCACCTATTGTCATGATTATTATGAT
GACGATTGAAAGTGCTGGCCAGTTTTGTACCCCGAGATGAAGTAAGGAGAGAC-3′)
. The final amplification product [1500 base pairs (bp)], which includes the mutant sequence 
in TM4 of human 5-HT2C, was generated with the outer oligonucleotides Nhe I–h5-HT2A/S 
(5′-TTTTGCTAGCATGGAACAAAAACTTATTTCTG-3′) and Bam HI–h5-HT2A/A (5′-
AAAAGGATCCTCACACACAGCTCACCTTTTC-3′). The final PCR product was digested 
with Nhe I and Bam HI and subcloned into the same restriction sites of pcDNA3.1–c-Myc–
5-HT2A. To generate chimeric human 5-HT2A with TM4 from human 5-HT2C, two 
overlapping PCR fragments were obtained using pcDNA3.1–c-Myc–5-HT2A as a template 
and the primers h5-HT2C –TM4/S (5′-
CCATCATGAAGATTGCTATTGTTTGGGCAATTTCTATAGGTGTATCAGTTCCTATCC
CTGTGTTTGGGCTACAGGACGATTCGAAGG-3′) and h5-HT2C–TM4/A (5′-
CACAGGGATAGGAACTGATACACCTATAGAAATTGCCCAAACAATAGCAATCTTCA
TGATGGCCTTAGTTCTGGAGTTGAAGC-3′). The final amplification product (1500 bp), 
which includes the mutant sequence in TM4 of human 5-HT2C, was generated with the outer 
oligonucleotides Nhe I–h5-HT2A/S (5′-
TTTTGCTAGCATGGAACAAAAACTTATTTCTG-3′) and Bam HI-h5-HT2A/A (5′-
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AAAAGGATCCTCACACACAGCTCACCTTTTC-3′). The final PCR product was digested 
with Nhe I and Bam HI and subcloned into the same restriction sites of pcDNA3.1–c-Myc–
5-HT2A. For 3-FRET experiments, the complementary DNAs (cDNAs) encoding Cerulean, 
mCitrine, and mCherry were amplified by PCR from their original vectors with the 
following primers: Not I–eYFP/S (5′-TTTTgcggccgcATGGTGAGCAAGGGCGAGGA-3′) 
and Xba I–eYFP/A (5′-TTTTtctagaTTACTTG-TACAGCTCGTCCA-3′). The PCR products 
were digested with Not I and Xba I and subcloned into the same sites of pcDNA3.1. The 
cDNAs encoding c-Myc–5-HT2A C-terminally tagged with enhanced cyan fluorescent 
protein (eCFP) and HA-mGlu2 C-terminally tagged with eYFP (22) were digested with Nhe 
I and Bam HI and subcloned into the same restriction sites of pcDNA3.1-Cerulean, 
pcDNA3.1-mCitrine, or pcDNA3.1-mCherry. The mutant mCitrine-Y67C [a nonfluorescent 
variant of mCitrine (57)] was constructed with the QuikChange II Site Directed Mutagenesis 
Kit. For BiFC studies, constructs were generated by subcloning the sequence encoding the 
N-terminal 172–amino acid fragment or the C-terminal 67–amino acid fragment of 
mCitrine. Overlapping PCR fragments were obtained using pcDNA3.1-mCitrine as template 
and the primers Not I–eCFP/S (5′-TTTT gcggccgcATGGTGAGCAAGGGCGAGGA-3′) 
and Xba I–N–eCFP/A (5′-TTTTtctagaTTAGATGTTGTGGCGGATCT-3′) to subclone the 
N-terminal fragment of mCitrine, and the primers Not I–C–eCFP/S (5′-
TTTTgcggccgcATGGAGGACGGCAGCGTGCA-3′) and Xba I–eCFP/A (5′-
TTTTtctagaTTAGATGTTGTGGCGGATCT-3′) to subclone the C-terminal fragment of 
mCitrine. The PCR products were digested with Not I and Xba I and subcloned into the 
same sites of pcDNA3.1 to obtain the constructs pcDNA3.1–mCi-N172 and pcDNA3.1–
mCi-C67. The form of HA-mGlu2 C-terminally tagged with eYFP (22) was digested with 
Nhe I and Bam HI and subcloned into the same restriction sites of pcDNA3.1–mCi-N172 
and pcDNA3.1–mCi-C67 to generate pcDNA3.1–HA–mGlu2–mCi-N172 and pcDNA3.1–
HA-mGlu2–mCi-C67.
Transient transfection of HEK 293 cells
HEK 293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM; glucose, 
4.5 g/liter) supplemented with 10% (v/v) dialyzed fetal bovine serum (FBS) at 37°C in a 5% 
CO2 humidified atmosphere. Experiments were performed with dialyzed FBS to exclude the 
serotonin and glutamate that nondialyzed FBS may contain. Transfection was performed 
with the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's 
instructions. The efficiency of cotransfection of eYFP- and mCherry-tagged constructs was 
56.48 ± 9.89%.
Measurement of [Ca2+]i
HEK 293 cells were transfected with the appropriate combination of expression plasmids as 
indicated in the figure legends; pcDNA3.1 (empty vector) was used to normalize the 
amounts of plasmid DNA in each transfection. Twenty-four hours later, cells were harvested 
and plated onto Delta T culture dishes (catalog no. 04200415B; Bioptechs Inc.) where they 
were cultured for an additional 24 hours before experiments were performed. Transfected 
cells were loaded with the Ca2+-sensitive dye Fura-2 (2.0 μM, catalog no. F1225; Life 
Technologies) and incubated for 45 min at 37°C under reduced light in Hanks' balanced salt 
solution (HBSS; catalog no. 14175; Life Technologies) and 0.04% Pluronic acid F-127 
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(catalog no. P6867; Invitrogen). Cells were incubated in HBSS for 20 min at 37°C under 
reduced light before experiments were performed. Cells were illuminated excited and 
imaged with an inverted epifluorescence microscope system (Olympus IX-70) equipped 
with a 20× objective (numerical aperture, 0.45) and a Uniblitz shutter, which was used to 
rapidly alternate the excitation wavelengths between 340 and 380 nm. Fura-2 fluorescence 
emission at 510 nm was monitored with an Evolution QEi CCD monochrome camera. 
MetaMorph imaging software was used to control all electronic hardware and image data 
processing. Sequential images were collected every 5 s, exposure to excitation was 200 ms 
per image, and all the experiments were performed in HBSS. Only individual cells that 
expressed detectable amounts of the respective fluorescent proteins (eYFP, mCherry, or 
both) were scored. Ratio images were presented in MetaMorph display mode, which 
associates the color hue with the excitation ratio value and the intensity of each hue with the 
source image brightness. Background fluorescence was subtracted from each raw image as 
follows. A region of interest was manually drawn in a region of no fluorescence adjacent to 
the fluorescent cells in the 380-nm channel image and then selected and transferred to the 
matched image acquired at 340 nm. The background amount was then subtracted from each 
pixel in each channel. Background-subtracted images were then used to calculate the 
340/380 nm ratio of each pixel, which was used to indicate changes in [Ca2+]i. After 
determination of the upper and lower thresholds, the ratio value of each pixel was associated 
with 1 of the 24 hues from blue (low [Ca2+]i) to red (high [Ca2+]i). The pooled average 
intensity-modulated display ratio measured from single cells was expressed as the mean of 
at least 20 cells with the vertical lines representing SEM.
FCM-based FRET
FCM-based FRET assays were performed as previously described (23).
Coimmunoprecipitation assays
Coimmunoprecipitation assays were performed as previously described (23).
3-FRET in living cells
3-FRET assays were performed as previously reported with minor modifications (26). 
Briefly, to detect 3-FRET in living cells, six filter channel combinations were established 
(that is, mCherry: excitation = 580/10 nm, emission = 630/60 nm; mCitrine: excitation = 
459/9 nm, emission = 535/30 nm; Cetrine: excitation = 425/10 nm, emission = 535/30; 
Cetrine/mCitrine/FRET: excitation = 425/10 nm, emission = 535/30 nm; Cetrine/mCitrine/
mCherry/FRET: excitation = 424/10 nm, emission = 630/60 nm; and mCitrine/mCherry/
FRET: excitation = 495/9 nm, emission = 630/60 nm), which enabled the acquisition of 
images from all three protein fluoro-phores and three raw FRET images. These images were 
used to calculate three corrected FRET images. MetaMorph imaging software was used to 
quantify the FRET images and to apply the necessary algorithms, pixel-by-pixel–based, to 
obtain a final image corresponding to the corrected and normalized FRET. Signal correction 
and normalization in 3-FRET was defined as previously reported (26).
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Molecular modeling
Active conformations of homology models of the mGlu2 and 5-HT2A receptors were built 
on the basis of the crystal structure of the β2-adrenergic receptor–Gs protein complex 
(Protein Data Bank ID: 3SN6) (58). The CRUSTALW server was used for sequence 
alignments, and this was followed by manual adjustment. Three-dimensional (3D) molecular 
models were generated with the program Modeller V9.5 (59). Ten homology models for 
each mGlu2 and 5-HT2A were generated, and model selection was performed on the basis of 
the internal DOPE (discrete optimized protein energy) scores in the Modeller program (60). 
2D Brownian dynamics (2D BD) simulations were performed with the selected mGlu2 and 
5-HT2A models (61, 62). One million 2D BD simulations were conducted on each of the 
mGlu2-mGlu2, 5-HT2A–5-HT2A, and 5-HT2A–mGlu2 homodimers and heterodimers. More 
than 120,000 complex models were obtained for each dimer from the 2D BD simulations. 
These results were filtered by adding restraints that enabled TM1, TM4, and TM1 domains 
to be located at the dimer interface for mGlu2-mGlu2, 5-HT2A–mGlu2, and 5-HT2A–5-
HT2A, respectively. The final dimer models were selected by visual inspection with the 
VMD (visual molecular dynamics) program (63). The mGlu2-mGlu2–5-HT2A-5-HT2A 
heteromer complexed with Gi and Gq was generated by superposition of the homodimers 
with the crystal structure of the β2-adrenergic receptor–Gs protein complex using the 
Chimera program (64).
[3H]Ketanserin, [3H]LY341495, and [35S]GTPγS binding assays in HEK 293 cells
Membrane preparations and [3H]ketanserin and [3H]LY341495 binding assays were 
performed as previously reported with minor modifications (22, 23). [35S]GTPγS binding 
experiments were initiated by the addition of membranes containing 35 μg of protein to an 
assay buffer [1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, 0.2 mM dithiothreitol (DTT), 50 
mM tris-HCl (pH 7.4), and 0.5 nM [35S]GTPγS], supplemented with 50 μM GDP, and 
containing the concentrations of ligands indicated in the figure legends. Nonspecific binding 
was determined in the presence of 10 μM GTPγS. Membrane preparations were incubated at 
30°C for 2 hours, and incubations were terminated by dilution with 3 ml of ice-cold 
incubation buffer. Free ligand was separated from bound ligand by rapid filtration under 
vacuum through GF/C glass fiber filters. The filters were then rinsed twice with 3 ml of ice-
cold incubation buffer, air-dried, and counted for radioactivity by liquid scintillation 
spectrometry using a Betaplate counter (Wallac-PerkinElmer).
Whole-cell patch-clamp recordings in HEK 293 cells stably expressing GIRK
Gi/o-dependent signaling can be detected through GIRK channels (35). This is a subfamily 
of Kir (inwardly rectifying K+) channels (or Kir3), which is sensitive to the Gβγ subunits of 
Gi/o proteins. Experiments were performed in HEK 293 cells stably transfected with pBI-
CMV1-GIRK1-GIRK4. Whole-cell patch-clamp current recordings were performed with a 
Patch Clamp L/M-EPC7 amplifier and Axon 8.1 software (Axon Instruments). Cells were 
trypsinized, resuspended in DMEM, and placed in the CO2 incubator for at least 3 hours for 
recovery. After recovery, the cells were placed on poly-D-lysine coverslips, left to attach for 
∼15 min, and transferred to the chamber of the patch-clamp setup with a bath solution 
containing 140 mM potassium gluconate, 2 mM CaCl2, 5 mM EGTA/KOH, 10 mM D-
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glucose, 10 mM Hepes-K, and 1 mM MgCl2. The composition of the pipette solution was 
140 mM potassium gluconate, 2 mM CaCl2, 5 mM EGTA/KOH, 10 mM D-glucose, 10 mM 
Hepes-K, 0.3 mM MgCl2, 2 mM NaATP, 0.1 mM GTPγS, and, when appropriate, 0.01 mM 
MPS (the selective Gβγ blocker). Osmolarity in both solutions was 340 mosmol, and the pH 
was 7.4. Upon formation of the whole-cell configuration, a voltage ramp from −100 mV to 
+100 mV was applied, and data were collected. At the end of the recordings, 4 mM BaCl2 
was applied to block potassium currents. The first few data points of the current versus time 
plot at −100 mV were averaged to obtain the basal current. Similarly, GTPγS-induced 
currents were calculated by averaging several current values at the peak of the effect. Values 
were divided by the membrane capacitance (pF) to normalize for the size of each cell. The 
basal current was subtracted from the GTPγS-induced current, and the difference was 
divided by the basal current.
Experimental animals
Experiments were performed on adult (10- to 14-week-old) male mice. 5-HT2A knockout 
(Htr2a−/−) mice of 129S6/Sv background have been previously described (65). mGlu2 
knockout (Grm2−/−) mice were obtained from the RIKEN BioResource Center, Japan (66), 
and backcrossed for at least 10 generations onto the 129S6/Sv background (67). For 
experiments involving genetically modified mice, wild-type littermates were used as 
controls. The Institutional Animal Use and Care Committee at the Icahn School of Medicine 
at Mount Sinai approved all of the experimental procedures.
Subcellular fractionation and PSD isolation
Subcellular fractionation was performed as previously described, with minor modifications 
(68). Briefly, mice were sacrificed by cervical dislocation. Bilateral frontal cortex samples 
(bregma 1.90 to 1.40 mm) from two mice were homogenized in 1.5 ml of 0.32 M sucrose, 
0.1 mM CaCl2 containing protease and phosphatase inhibitors (Sigma-Aldrich). The 
homogenate was brought to a final concentration of 1.25 M sucrose by adding 2 M sucrose 
and 0.1 mM CaCl2. The homogenate was then placed in an ultracentrifuge (Optima XE-100 
Ultracentrifuge, Beckman Coulter), overlaid with 1 M sucrose, and subjected to 
centrifugation at 100,000g for 3 hours at 4°C. The synaptosomal fraction was collected at 
the interface between the 1.25 and 1 M sucrose solutions. To obtain the synaptic junctions, 
the synaptosomal fraction was diluted with 20 mM tris-HCl, 0.1 mM CaCl2 (pH 6.0) 
containing 1% Triton X-100, mixed for 20 min at 4°C, and then centrifuged at 40,000g for 
20 min at 4°C. The pellet containing the isolated synaptic junctions was collected. To 
separate presynaptic proteins from the PSD, the pellet was resuspended in 20 mM tris-HCl 
(pH 8.0), 0.1 mM CaCl2, containing 1% Triton X-100. The mixture was again mixed for 20 
min at 4°C and centrifuged at 40,000g for 20 min at 4°C. The insoluble pellet containing the 
PSD fraction and the supernatant containing the presynaptic fraction were collected at stored 
at −80°C until use.
Western blotting
For Western blotting analysis, equal amounts of proteins (150 μg) were resolved by 10% 
SDS-PAGE and transferred to nitrocellulose membranes by electroblotting. Detection of 
proteins by Western blotting with anti-mGlu2 (catalog no. ab15672; Abcam), anti–5-HT2A 
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(catalog no. RA24288; Neuromics), anti–β-actin (catalog no. ab8227; Abcam), anti-PSD95 
(catalog no. 2507; Cell Signaling), and anti–syntaxin-1 (catalog no. AB5820; Millipore) 
antibodies was performed with the enhanced chemiluminescence system according to the 
manufacturer's instructions. The specificity of the primary antibody (catalog no. ab15672; 
Abcam) against mGlu2 receptors was previously confirmed in experiments with knockout 
mice (23, 24). For confirmation of specificity of the primary antibody (catalog no. 
RA24288; Neuromics) against 5-HT2A receptors in experiments with knockout mice, see 
fig. S9.
Immunocytochemistry
Experiments were performed as previously reported (23).
Postmortem human brain tissue samples
Human brains were obtained at autopsies performed between 1995 and 2007 in the Basque 
Institute of Legal Medicine, Bilbao, Spain, in compliance with policies of research and 
ethical boards for postmortem brain studies. Deaths were subjected to retrospective 
searching for previous medical diagnosis and treatment using examiner's information and 
records of hospitals and mental health centers. After searching of antemortem information 
was fulfilled, 27 subjects who had met the criteria of schizophrenia according to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) were selected. A 
toxicological screening for antipsychotics, other drugs, and ethanol was performed on blood, 
urine, liver, and gastric content samples. Subjects who gave negative results for 
antipsychotic drugs in the toxicological screening were considered to be antipsychotic-free 
at death. The toxicological assays were performed at the National Institute of Toxicology, 
Madrid, Spain, with various standard procedures, including radioimmunoassay, enzymatic 
immunoassay, high-performance liquid chromatography, and gas chromatography–mass 
spectrometry. Controls for the present study were chosen among the collected brains on the 
basis, whenever possible, of the following cumulative criteria: (i) negative medical 
information on the presence of neuropsychiatric disorders or drug abuse; (ii) appropriate 
gender, age, postmortem delay (time between death and autopsy), and freezing storage time 
to match each subject in the schizophrenia group; (iii) sudden and unexpected death (motor 
vehicle accidents); and (iv) toxicological screening for psychotropic drugs with negative 
results except for ethanol. Specimens of prefrontal cortex (Brodmann's area 9) were 
dissected at autopsy (0.5 to 1 g of tissue) on an ice-cooled surface and immediately stored at 
−80°C until required for use. The definitive pairs of antipsychotic-free schizophrenics, 
antipsychotic-treated schizophrenics, and respective matched controls are shown in table S1. 
Pairs of samples from schizophrenia patients and matched controls were processed 
simultaneously and under the same experimental conditions. Brain samples were assayed for 
pH and RNA integrity number as previously reported (see table S1) (69).
Scintillation proximity assay for [35S]GTPγS binding in mouse and human frontal cortex
Membrane preparations were performed as previously reported (70). [35S]GTPγ S binding 
assays were performed in 96-well isoplates (Perkin-Elmer). [35S]GTPγS binding 
experiments were initiated by the addition of membrane preparations containing 15 μg of 
protein to an assay buffer [1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, 1.0 mM DTT, 50 
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mM tris-HCl (pH 7.4), and 0.4 nM [35S]GTPyS], supplemented with either 100 μM GDP 
(for anti-Gαi1,2,3 experiments) or 50 μM GDP (anti-Gαq/11 experiments), and containing the 
concentrations of ligands indicated in the figure legends (for a final volume of 200 μl per 
well). Nonspecific binding was determined in the presence of 100 μM GTPγS. Membrane 
preparations were incubated at 30°C for 2 hours with gentle agitation (450 rpm; ELMI 
Digital Thermostatic Shaker DTS-4), after which 20 μl of detergent solution (1.0% Igepal, 
0.1% sodium deoxycholate, and protease inhibitors) was added and samples were then 
incubated at 22°C for 30 min with gentle agitation (400 rpm). After solubilization, 10 μl of 
either anti-Gαi12,3 (sc-262) or anti-Gαq/11 (sc-392) antibody was added at a 1:20 dilution 
and incubated at 22°C for 90 min. Finally, after the addition of 50 μl of scintillation 
proximity assay (SPA) polyvinyltoluene protein A SPA beads (2:3 dilution; PerkinElmer), 
the plates were incubated at 22°C for 2 hours with gentle agitation. Plates were centrifuged 
at 1000g for 15 min, and the scintillation signal was measured with a MicroBeta TriLux 
scintillation counter (PerkinElmer).
Statistical analysis
All statistical analyses were performed with GraphPad Prism software version 6. 
Concentration-response curves (Figs. 1, E and I, 2L, and 3D) were analyzed with the 
following equation: Y = Ymin + (Ymax–Ymin) • [X]/([X] + K0.5). Restricting the parameter 
Ymin to be zero, the equation was also used to fit the nonlinear curve for the radioligand 
binding saturation curves (fig. S7), with Ymax renamed as Bmax, and for the FCM-based 
FRET data (fig. S6, A and C), with Ymax renamed as FRETmax. An extra sum of square (F 
test) was used to determine the statistical difference for the simultaneous analysis of binding 
saturation curves (fig. S7), FCM-based FRET data (fig. S6, A and C), and concentration-
response curves (Figs. 1, E and I, 2L, and 3D). The statistical significance of experiments 
involving two groups was assessed by Student's t test, whereas the statistical significance of 
experiments involving three or more groups was assessed by one-way ANOVA followed by 
Bonferroni's post hoc test. The statistical significance of experiments involving three or 
more groups and two or more experimental conditions was assessed by two-way ANOVA 
followed by Bonferroni's post hoc test. The level of significance was chosen at P = 0.05. All 
data are presented as means ± SEM.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. The ability of the mGlu2/3 receptor agonist LY379268 to stimulate Ca2+ release requires 
the assembly of 5-HT2A–mGlu2 hetero-mers in HEK 293 cells
(A to C) HEK 293 cells transfected with the control plasmid pcDNA3.1 or trans-fected with 
plasmids encoding mGlu2-eYFP and 5-HT2A–mCherry alone or in combination were loaded 
with Fura-2 and monitored for [Ca2+]i signals after sequential stimulation with 100 μM 
LY379268 (an mGlu2/3 receptor agonist) and 10 μM 5-HT. (A) Images captured before and 
after drug additions are representative of three independent experiments. (B) Time course of 
Ca2+ release in HEK 293 cells expressing the indicated constructs. The arrowheads indicate 
the times when the drugs were added. (C) Analysis of the fold increase in [Ca2+]i in cells 
expressing the indicated combination of receptors. Data in (B) and (C) are means ± SEM of 
five to eight experiments. (D) HEK 293 cells transfected withpcDNA3.1 as a control or 
cotransfected with the indicated ratios of plasmids encoding eYFP - and mCherry-tagged 
receptors were sequentially stimulated withLY379268 and 5-HT before Ca2+ release was 
measured. Data aremeans ± SEM of three experiments. (E) HEK 293 cells cotransfected 
with plasmids encoding mGlu2-eYFP and 5-HT2A–mCherry were stimulated with the 
indicated concentrations of LY379268 (left panel)and then with 5-HT (right panel)before 
Ca2+ release was measured. Data are means ± SEM of 3 to 10 experiments. (F) HEK 293 
cells coexpressing mGlu2-eYFP and 5-HT2A–mCherry were treated with vehicle (–) or were 
sequentially stimulated with LY379268 and 5-HT in the absence or presence of 10 μM 
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LY341495 (an mGlu2/3 receptor antagonist). Data are means ± SEM of three to five 
experiments. (G) HEK 293 cells transfected with control plasmid or cotransfected with 
plasmids encoding the indicated eYFP- and mCherry-tagged constructs were sequentially 
stimulated with LY379268 (white bars) and 5-HT (black bars) before Ca2+ release was 
measured. Data are means ± SEM of three to six experiments. *P < 0.05, **P < 0.01, and 
***P < 0.001 by Bonferroni's post hoc test of one-way analysis of variance (ANOVA) (C, D, 
G, and H) or by Student's t test (F). (H) LY379268-stimulated [35S]GTPγS binding in 
plasma membrane preparations of HEK 293 cells transfected with plasmids encoding the 
indicated eYFP- or mCherry-tagged receptors. Data are means ± SEM of two or three 
experiments.
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Fig. 2. Coupling to both Gi/o and Gq/11 proteins is necessary for LY379268-induced Ca2+ release 
in HEK 293 cells expressing 5-HT2A–mGlu2 heteromers
(A) Effect of 20-min pretreatment with 10 μM M100,907 on Ca2+ release in HEK 293 cells 
coexpressing mGlu2-eYFP and 5-HT2A–mCherry after sequential stimulation with 100 μM 
LY379268 (white bars) and 10 μM 5-HT (black bars). (B) Measurement of Ca2+ release in 
HEK 293 cells transfected with control plasmid or coexpressing mGlu2-eYFP and either 5-
HT2A–mCherry or 5-HT2A–I181D–mCherry after sequential stimulation with LY379268 
and 5-HT. (C) Effect of 20-min pretreatment with 1 μM UBO-QIC (a selective Gq/11 
inhibitor) or vehicle on Ca2+ release in HEK 293 cells coex-pressing mGlu2-eYFP and 5-
HT2A–mCherry after sequential stimulation with LY379268 and 5-HT. (D) Effect of 20-min 
pretreatment with 10 μM U73122 (a selective PLC-γ inhibitor) or vehicle on Ca2+ release in 
HEK 293 cells coexpressing mGlu2-eYFP and 5-HT2A–mCherry after sequential 
stimulation with LY379268 and 5-HT. (E) Measurement of Ca2+ release in HEK293 cells 
transfected with control plasmid or coexpressing 5-HT2A–mCherry with either mGlu2-eYFP 
or mGlu2-F756S–eYFP after sequential stimulation with LY379268 and 5-HT. (F) Effect of 
overnight incubation with PTX (500 ng/ml) or vehicle on Ca2+ release in HEK 293 cells 
coexpressing mGlu2-eYFP and 5-HT2A–mCherry after sequential stimulation with 
LY379268 and 5-HT. (G) Effect of 30-min pretreatment with 10 μM NF023 (a selective 
Gαi/o inhibitor) or vehicle on Ca2+ release in HEK 293 cells coexpressing mGlu2-eYFP and 
Moreno et al. Page 31
Sci Signal. Author manuscript; available in PMC 2017 January 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
5-HT2A–mCherry after sequential stimulation with LY379268 and 5-HT. (H) Effect of 60-
min pretreatment with 10 μM MPS (a selective Gβγ blocker) or vehicle on Ca2+ release in 
cells coexpressing mGlu2-eYFP and 5-HT2A–mCherry after sequential stimulation with 
LY379268 and 5-HT. (I and J) Effect of 10 μM MPS on G protein–coupled inwardly 
rectifying potassium (GIRK) currents in response to 100 μM GTPγS included in the patch 
pipette. Representative traces (I) and the summary of data (J) from whole-cell patch-clamp 
recordings show the membrane-permeable sequence (MPS)–dependent inhibition of GTPγS-
induced GIRK currents in HEK 293 cells expressing GIRK1 and GIRK4. Barium (Ba) 
inhibited GIRK currents and enabled the subtraction of GIRK-independent currents. (K) 
Measurement of Ca2+ release in response to sequential stimulation with LY379268 and 5-
HT in HEK 293 cells transfected with control plasmid or cotransfected with plasmids 
encoding the indicated eYFP- and mCherry-tagged constructs or with plasmids encoding the 
indicated mGlu2 mutant. Data are means ± SEM of 3 or 4 experiments (A, C, D, G, and H), 
3 to 5 experiments (E), 4 or 5 experiments (F), 3 to 6 experiments (B and K), or 10 
experiments (J). *P < 0.05, **P < 0.01, and ***P < 0.001 by Bonferroni's post hoc test of 
one-way ANOVA (A to H and K) or Student's t test (J). (L) LY379268-stimulated 
[35S]GTPγS binding in plasma membrane preparations of HEK 293 cells expressing the 
indicated eYFP- or mCherry-tagged receptors or coexpressing the indicated mCi-N172–or 
mCi-C67–tagged constructs. Data are means ± SEM of two or three experiments each 
performed in triplicate. n.s., not significant.
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Fig. 3. The relative orientation of the two mGlu2 protomers affects 5-HT2A receptor–dependent 
Gq/11 coupling
(A and B) Cartoon representation of the relative positions of the components of the 5-HT2A–
mGlu2 heteromeric receptor complex that are necessary to induce Ca2+ release in the 
presence of the mGlu2/3 agonist LY379268 based on the mGlu2/mGlu3 chimeric and single 
point mutation constructs expressed in HEK 293 cells. (C) Measurement of Ca2+ release in 
HEK 293 cells that were left untransfected or were cotransfected with plasmids encoding the 
indicated constructs after sequential stimulation with LY379268 and 5-HT. Data are means ± 
SEM of three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by 
Bonferroni's post hoc test of one-way ANOVA. (D) Measurement of LY379268-stimulated 
[35S]GTPγS binding in plasma membrane preparations of HEK 293 cells coexpressing mCi-
N172–and mCi-C67–tagged receptors. Data are means ± SEM of four to eight experiments, 
each performed in triplicate.
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Fig. 4. Single-cell imaging and structure of oligomers of the 5-HT2A–mGlu2 het-eromeric 
receptor complex
(A to C) Top: Cartoons illustrate the basis of direct and sequential FRET. Bottom: Three-
color FRET (3-FRET) signals in cells expressing c-Myc–5-HT2A–Cerulean, HA-mGlu2-
mCherry, and either c-Myc–5-HT2A–mCitrine or c-Myc–5-HT2A–Y67C-mCitrine. (A) 
Sequential 3-FRET was calculated by subtracting the signal in cells expressing Cerulean, 
mCitrine, and mCherry. Data are means ± SEM of 16 to 20 cells per group in three 
independent experiments. **P < 0.01 by Bonferroni's post hoc test of one-way ANOVA. (B 
and C) Single FRET signals in cells expressing c-Myc–5-HT2A–Cerulean/c-Myc–5-HT2A–
mCitrine and HA-mGlu2-mCherry. The single FRET signal from c-Myc–5-HT2A–
Cerulean/c-Myc–5-HT2A–mCitrine (B) and the single FRET signal from c-Myc–5-HT2A–
mCitrine/HA-mGlu2-mCherry (C) were used to establish the appropriate conditions to 
measure both direct two-protein and sequential three-protein FRET. Data are means ± SEM 
of 16 to 20 cells per group in three independent experiments. ***P < 0.001 by Student's t 
test. (D and E) TM4 of 5-HT2A mediates complex formation with the mGlu2 receptor. Top: 
Schematic of the 5-HT2A/5-HT2C chimeras studied. Bottom: HEK 293 cells coexpressing 
HA-mGlu2 and either c-Myc–5-HT2A or c-Myc–5-HT2C (D) or coexpressing HA-mGlu2 
and either c-Myc–5-HT2AΔTM1 or c-Myc–5-HT2AΔTM4 (E) were subjected to 
coimmunoprecipitation (IP) with antibody against the c-Myc tag and then were analyzed by 
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Western blotting (WB) with anti-bodies against the indicated tags. As controls, HEK 293 
cells separately expressing the c-Myc–or HA-tagged forms of the indicated receptors were 
mixed. Western blots are representative of three independent experiments.
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Fig. 5. Model for the docking of Gi/o onto the 5-HT2A–mGlu2 heteromeric receptor complex
(A to C) Ribbon representation of the vertical (A), extracellular (B), and cytoplasmic (C) 
views of the mechanism by which coupling of Gi/o proteins to the mGlu2 protomer located 
distal to the 5-HT2A component is necessary to enable allosteric crosstalk with 5-HT2A and 
consequently activate Gq/11-dependent signaling. The homodimeric interfaces of mGlu2 and 
5-HT2A involve residues from TM1. The interface of the 5-HT2A–mGlu2 heteromeric 
complex involves residues from TM4. αAH, α-helical domain of the Gα subunit; αRas, Ras-
like domain of the Gα subunit.
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Fig. 6. Activation of Gq/11 by the mGlu2/3 agonist LY379268 is reduced in the frontal cortex of 5-
HT2A knockout mice
(A and B) Validation of the subcellular fractionation protocol performed to isolate PSDs and 
PAZs from the mouse frontal cortex. Equal amounts of proteins from mouse frontal cortex 
PSD and PAZ fractions were resolved by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and analyzed by Western blotting with antibodies against postsynaptic (PSD-95) and 
presynaptic (syntaxin-1) markers (A), as well as with antibodies specific for mGlu2 and 5-
HT2A (B). Western blots are representative of three independent experiments. (C and D) 
[35S]GTPγS binding to frontal cortex membrane preparations of wild-type and mGlu2 
knockout mice after treatment with vehicle or 10 μM LY379268 in the absence or presence 
of 10 μM LY341495 (the mGlu2/3 receptor antagonist) followed by immunopre-cipitation 
with anti-Gαi1,2,3 (C) or anti-Gαq/11 (D) antibodies. Data are means ± SEM of three or four 
independent experiments, performed in triplicate or quintuplicate for each condition. (E and 
F) [35S] GTPγS binding to frontal cortex membrane preparations of wild-type and 5-HT2A 
knockout mice after treatment with vehicle or 10 μM LY379268 in the absence or presence 
of 10 μM LY341495 followed by immunoprecipitation with anti-Gαi1,2,3 (E) or anti-Gαq/11 
(F) antibodies. Data are means ± SEM of three or four independent experiments, performed 
in triplicate or quintuplicate for each condition. *P < 0.05, **P < 0.01, and ***P < 0.001 by 
Bonferroni's post hoc test of two-way ANOVA.
Moreno et al. Page 37
Sci Signal. Author manuscript; available in PMC 2017 January 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 7. Activation of Gq/11 by the mGlu2/3 agonist LY379268 is dysregulated in the postmortem 
brains of schizophrenic subjects
(A and B) [35S]GTPγS binding in postmortem frontal cortexes of schizophrenic subjects and 
normal controls after treatment with vehicle or the indicated concentrations of LY379268 in 
the absence or presence of 10 μM LY341495 (the mGlu2/3 receptor antagonist) followed by 
immunoprecipitation with anti-Gαi1,2,3 (A) or anti-Gαq/11 (B) antibodies. Data are means ± 
SEM of 27 independent experiments, performed in triplicate or quintuplicate for each 
condition. See table S1 for demographic information and table S2 for pharmacological data. 
**P < 0.01 and ***P < 0.001 by Bonferroni's post hoc test of two-way ANOVA.
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